Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
4-Year outcome of bioactive stents versus everolimus-eluting stents in acute coronary syndrome
Scandinavian Cardiovascular Journal, Volume 50, No. 4, Year 2016
Notification
URL copied to clipboard!
Description
Objectives: The BASE-ACS trial demonstrated non-inferiority of titanium-nitride-oxide-coated bioactive stents (BAS), versus everolimus-eluting stents (EES), for major adverse cardiac events (MACE) at 1- and 2-year follow-up, in patients with acute coronary syndrome (ACS). We presented the 4-year outcome of the BASE-ACS trial. Design: We randomized 827 patients with ACS to receive either BAS (417) or EES (410). MACE was a composite of cardiac death, non-fatal myocardial infarction (MI) or ischemia-driven target lesion revascularization (TLR) at 12-month follow-up. Analyses were performed by intention to treat. Follow-up was planned at 12 months, and yearly thereafter for 5 years. Results: Four-year clinical follow-up was completed in 753 (91.1%) patients. At 4 years, BAS were non-inferior to EES for MACE (14.7% versus 17.8%, respectively; p = 0.24 for superiority; p = 0.001 for non-inferiority). Non-fatal MI was less frequent with BAS (5.0% versus 9.2%, respectively; p = 0.025). Cardiac death and ischemia-driven TLR were comparable (2.9% versus 3.5%, and 8.6% versus 9.2%; p = 0.62 and p = 0.80, respectively). Independent predictors of MACE were calcified lesions (HR 1.54, p = 0.021), the number of vessels treated (HR 1.53, p = 0.025), and reference vessel diameter (HR 0.54, p = 0.006). Conclusions: In patients presenting with ACS, BAS was associated with a clinical outcome non-inferior to EES at 4-year follow-up. © 2016 Informa UK Limited, trading as Taylor & Francis Group.
Authors & Co-Authors
Karjalainen, Pasi Paavo
Finland, Pori
Satakunta Central Hospital
Niemelä, Matti J.
Finland, Oulu
Oulun Yliopisto
Pietilä, Mikko J.
Finland, Turku
Turun Yliopistollinen Keskussairaala
de Belder, Adam J.
United Kingdom, Worthing
University Hospitals Sussex Nhs Foundation Trust
Nammas, Wail M.
Finland, Pori
Satakunta Central Hospital
Statistics
Citations: 9
Authors: 5
Affiliations: 6
Identifiers
Doi:
10.1080/14017431.2016.1177198
ISSN:
14017431
Research Areas
Noncommunicable Diseases
Study Design
Cohort Study